In 2020, a translational study on breast cancer suggested that olaparib was equally effective in patients with advanced breast cancer having somatic BRCA mutations, further suggesting that PARP inhibitors are not limited to germline BRCA mutations (86). This evidence concerns the gene PARP1 and breast cancer.